SCHEMBL13135677

SCHEMBL13135677

CN1CCC(c2nc3ccc(F)cc3o2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ MPO P05164 1/20 0.47
▸ GAA P10253 1/20 0.44
▸ THRB P10828 1/20 0.43
▸ LMNA P02545 3/20 0.41
▸ GABRP O00591 1/20 0.41
▸ GABRD O14764 1/20 0.41
▸ GABRA1 P14867 1/20 0.41
▸ GABRB1 P18505 1/20 0.41
▸ GABRG2 P18507 1/20 0.41
▸ GABRB3 P28472 1/20 0.41
▸ GABRA5 P31644 1/20 0.41
▸ GABRA3 P34903 1/20 0.41
▸ GABRA2 P47869 1/20 0.41
▸ GABRB2 P47870 1/20 0.41
▸ GABRA4 P48169 1/20 0.41
▸ GABRE P78334 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20304407 0.83 LMNA (0.41) MEN1KMT2ASMN1; SMN2THRBLMNA
SCHEMBL7531642 0.81 ACHE (0.43) MEN1KMT2ASMN1; SMN2MPODRD2
SCHEMBL13135678 0.81 LMNA (0.53) GAALMNAGABRPGABRDGABRA1
SCHEMBL2859330 0.80 MPO (0.67) METMEN1KMT2ASMN1; SMN2MPO
SCHEMBL13810503 0.80 LMNA (0.61) MEN1KMT2ATHRBLMNANPSR1
SCHEMBL14136368 0.76 RAB9A (0.49) SMN1; SMN2MPOTHRBLMNAGABRP
SCHEMBL29780578 0.75 RAB9A (0.48) MEN1KMT2ASMN1; SMN2MPOTHRB
SCHEMBL20304443 0.75 RAB9A (0.48) MEN1KMT2ASMN1; SMN2MPOTHRB
SCHEMBL15944009 0.75 MPO (0.53) METMEN1KMT2ASMN1; SMN2MPO
SCHEMBL14555098 0.75 MPO (0.53) METMEN1KMT2ASMN1; SMN2MPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 — — US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 MET 255/4885MEN1 3295/4885KMT2A 1595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback